EE05374B1 - KompositsioonÁneurotserebrovaskulaarseteÁh„ireteÁravimiseksÁningÁmeetodÁsellesÁsisalduvaÁkurkumi?liÁvalmistamiseks - Google Patents

KompositsioonÁneurotserebrovaskulaarseteÁh„ireteÁravimiseksÁningÁmeetodÁsellesÁsisalduvaÁkurkumi?liÁvalmistamiseks

Info

Publication number
EE05374B1
EE05374B1 EEP200400097A EEP200400097A EE05374B1 EE 05374 B1 EE05374 B1 EE 05374B1 EE P200400097 A EEP200400097 A EE P200400097A EE P200400097 A EEP200400097 A EE P200400097A EE 05374 B1 EE05374 B1 EE 05374B1
Authority
EE
Estonia
Prior art keywords
neurone
cerebrovascular
preparation
treatment
composition
Prior art date
Application number
EEP200400097A
Other languages
English (en)
Estonian (et)
Inventor
Madhur�Ray
Raghwendra�Pal
Satyawan�Singh
Nandoo�Mal�Khanna
Original Assignee
Council�of�Scientific�and�Industrial�Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council�of�Scientific�and�Industrial�Research filed Critical Council�of�Scientific�and�Industrial�Research
Publication of EE200400097A publication Critical patent/EE200400097A/xx
Publication of EE05374B1 publication Critical patent/EE05374B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
EEP200400097A 2001-12-14 2002-12-14 KompositsioonÁneurotserebrovaskulaarseteÁh„ireteÁravimiseksÁningÁmeetodÁsellesÁsisalduvaÁkurkumi?liÁvalmistamiseks EE05374B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34016501P 2001-12-14 2001-12-14
PCT/IB2002/005366 WO2003051380A2 (fr) 2001-12-14 2002-12-14 Composition destinee au traitement de troubles neurocerebrovasculaires

Publications (2)

Publication Number Publication Date
EE200400097A EE200400097A (et) 2004-10-15
EE05374B1 true EE05374B1 (et) 2011-02-15

Family

ID=23332163

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200400097A EE05374B1 (et) 2001-12-14 2002-12-14 KompositsioonÁneurotserebrovaskulaarseteÁh„ireteÁravimiseksÁningÁmeetodÁsellesÁsisalduvaÁkurkumi?liÁvalmistamiseks

Country Status (19)

Country Link
US (2) US20060051438A1 (fr)
EP (1) EP1453528B1 (fr)
JP (1) JP4695839B2 (fr)
KR (1) KR101001815B1 (fr)
CN (1) CN100528149C (fr)
AU (2) AU2002348802A1 (fr)
BR (1) BR0214962A (fr)
CA (1) CA2473874C (fr)
DE (1) DE60233069D1 (fr)
EA (1) EA007067B1 (fr)
EE (1) EE05374B1 (fr)
GE (1) GEP20084442B (fr)
LT (1) LT5284B (fr)
LV (1) LV13250B (fr)
MX (1) MXPA04005680A (fr)
NO (1) NO332066B1 (fr)
UA (1) UA82057C2 (fr)
WO (1) WO2003051380A2 (fr)
ZA (1) ZA200404648B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115366A1 (fr) * 2004-05-31 2005-12-08 Kaneka Corporation Agent pour prévenir/améliorer les maladies liées au mode de vie contenant un composant d'huile essentielle de curcuma
WO2006118079A1 (fr) * 2005-04-28 2006-11-09 Arata Yamasaki Agent anti-vieillissement pour la peau
US10543277B2 (en) 2005-05-30 2020-01-28 Arjuna Natural Private Limited Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof
US10286027B2 (en) 2005-05-30 2019-05-14 Arjuna Natural Extracts, Ltd. Sustained release formulations of curcuminoids and method of preparation thereof
DK1890546T3 (en) 2005-05-30 2019-03-11 Benny Antony Process for improving the bioavailability of curcumin
US7883728B2 (en) 2005-05-30 2011-02-08 Arjuna Natural Extracts, Ltd. Composition to enhance the bioavailability of curcumin
US9492402B2 (en) 2005-05-30 2016-11-15 Benny Antony Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof
US8859020B2 (en) 2005-05-30 2014-10-14 Benny Antony Treatment of alzheimer's with a curcuminoid mixture and essential oil of turmeric having 45% Ar-turmerone
JP4980626B2 (ja) * 2006-02-28 2012-07-18 ポーラ化成工業株式会社 プラスミノーゲンアクチベーターインヒビターｉ阻害剤及びそれを配合してなる食品組成物
JP5207341B2 (ja) * 2006-10-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
MX2010003726A (es) * 2007-10-03 2010-09-14 Sabell Corp Composiciones herbarias y metodos de tratamiento de trastornos hepaticos.
JP2012519197A (ja) * 2009-03-05 2012-08-23 キージーン・エン・フェー Ｒ−クルクメンをベースとする植物揮発性物質
DK2458983T3 (en) 2009-07-31 2015-10-05 Cognition Therapeutics Inc INHIBITORS OF cognitive impairment
JP5764288B2 (ja) 2009-09-24 2015-08-19 ハウス食品グループ本社株式会社 ウコン抽出物とガジュツ抽出物とを含有する組成物
JP5578822B2 (ja) * 2009-09-25 2014-08-27 株式会社ピカソ美化学研究所 アセチルコリンエステラーゼ阻害剤
AU2012212219B2 (en) 2011-02-02 2017-03-23 Cognition Therapeutics, Inc. Isolated compounds from turmeric oil and methods of use
US9068141B2 (en) 2011-03-29 2015-06-30 Council Of Scientific & Industrial Research Process for the modification of Curcuma aromatica essential oil
GB201111319D0 (en) 2011-07-04 2011-08-17 Univ Leuven Kath Anticonvulsant activity of tumeric oil and bisabolene sesquiterpenoids of curcuma longa
KR101890322B1 (ko) * 2012-01-13 2018-08-21 주식회사 엘지생활건강 피부 주름 개선 및 탄력 증진용 조성물
CN102697757B (zh) * 2012-05-18 2014-06-04 广州军区广州总医院 对羟基苄叉丙酮在制备预防和/或治疗脑病药物中的应用
JP2014201528A (ja) * 2013-04-02 2014-10-27 クラシエ製薬株式会社 抗酸化剤
EP3099296B1 (fr) 2014-01-31 2019-01-30 Cognition Therapeutics, Inc. Dérivé d'isoindoline, compositions et méthodes de traitement d'une maladie neurodégénérative
CN106822071B (zh) * 2014-09-23 2019-12-27 桂林八加一药业股份有限公司 一种用于治疗冠心病、高脂血症的中药有效部位、制备方法及从中分离有效成分的方法
CN105738546B (zh) * 2014-12-12 2020-01-21 桂林八加一药业股份有限公司 毛郁金药材指纹图谱的建立方法及其指纹图谱
CN105055449B (zh) * 2015-07-27 2019-08-09 中国科学院西北高原生物研究所 一种具有抗炎镇痛活性的塞隆骨提取物、制备方法及中药制剂
CN106491997A (zh) * 2016-12-29 2017-03-15 王明金 一种抗精神障碍的中药组合物及其制备方法
CN106491996A (zh) * 2016-12-29 2017-03-15 王明金 一种治疗狂躁症的中药组合物及其制备方法
CN106492137A (zh) * 2016-12-29 2017-03-15 王明金 一种治疗抑郁症的中药组合物及其制备方法
CN106511784A (zh) * 2016-12-29 2017-03-22 王明金 一种治疗精神疾病的中药组合物及其制备方法
CA3063338A1 (fr) * 2017-05-12 2019-12-05 House Wellness Foods Corporation Composition anti-inflammatoire
US11214540B2 (en) 2017-05-15 2022-01-04 Cognition Therapeutics, Inc. Compositions for treating neurodegenerative diseases
US10391138B2 (en) * 2017-07-11 2019-08-27 Muniyal Ayurvedic Research Centre Multidimensional approach for Cancer treatment
CN108498755B (zh) * 2018-04-17 2021-04-09 贾洪章 治疗心脑血管疾病的中药组合物及其制备方法和用途
JPWO2020004357A1 (ja) * 2018-06-29 2021-07-08 ハウスウェルネスフーズ株式会社 アルツハイマー病の治療、予防又は改善用組成物、脳神経細胞死の抑制用組成物、アミロイドβペプチドで誘導されるミクログリアの活性化の抑制用組成物、及び、アミロイドβペプチドで誘導されるＰＧＥ２、ＴＮＦ−α又はＩＬ−１β産生の抑制用組成物
CN111617060A (zh) * 2020-05-29 2020-09-04 广东工业大学 吉马酮的应用
CN111617059B (zh) * 2020-05-29 2023-07-25 广东工业大学 莪术二酮的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU83350A1 (fr) 1981-05-08 1983-03-24 Oreal Composition destinee au traitement des fibres keratiniques a base de polymere cationique et de polymere anionique a groupements vinylsulfoniques et procede de traitement la mettant en oeuvre
IN162441B (fr) 1984-12-26 1988-05-28 Council Scient Ind Res
US4842859A (en) * 1986-09-08 1989-06-27 Yaguang Liu Pharmaceutical compositions for reducing hyperlipidemia and platelet-aggregation
US5120538A (en) * 1990-02-05 1992-06-09 Pt Darya-Varia Laboratoria Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
CN1100321A (zh) * 1994-03-27 1995-03-22 叶启智 灵猫香或其复方药用针剂
AU2300001A (en) * 1999-10-22 2001-05-08 Board Of Trustees Of The University Of Illinois, The Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
DE10029770A1 (de) * 2000-06-16 2001-12-20 Transmit Technologietransfer Verwendung von Curcuminen zur Behandlung von soliden Tumoren,insbesondere von Hirntumoren
JP2002030081A (ja) * 2000-07-13 2002-01-29 Shiseido Co Ltd ジアリールヘプタノイド誘導体及びマトリックスメタロプロテアーゼ活性阻害剤
KR20020073847A (ko) * 2001-03-16 2002-09-28 주식회사 바이오시너젠 쿠르쿠민 또는 울금 추출물을 포함하는 치매 예방 및치료용 조성물

Also Published As

Publication number Publication date
NO20043000L (no) 2004-07-13
EE200400097A (et) 2004-10-15
WO2003051380A3 (fr) 2004-06-17
JP4695839B2 (ja) 2011-06-08
CN1615144A (zh) 2005-05-11
EA007067B1 (ru) 2006-06-30
KR101001815B1 (ko) 2010-12-15
LT5284B (lt) 2005-11-25
CN100528149C (zh) 2009-08-19
US20060051438A1 (en) 2006-03-09
MXPA04005680A (es) 2004-10-15
LT2004060A (en) 2005-06-27
EA200400807A1 (ru) 2004-12-30
LV13250B (en) 2006-02-20
BR0214962A (pt) 2004-12-14
DE60233069D1 (de) 2009-09-03
EP1453528A2 (fr) 2004-09-08
EP1453528B1 (fr) 2009-07-22
NO332066B1 (no) 2012-06-18
AU2009212969A1 (en) 2009-10-01
AU2009212969B2 (en) 2011-06-02
WO2003051380A2 (fr) 2003-06-26
CA2473874C (fr) 2011-11-22
UA82057C2 (en) 2008-03-11
US20100093870A1 (en) 2010-04-15
CA2473874A1 (fr) 2003-06-26
JP2005516930A (ja) 2005-06-09
KR20040073478A (ko) 2004-08-19
GEP20084442B (en) 2008-08-10
ZA200404648B (en) 2005-11-30
AU2002348802A1 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
EE05374B1 (et) KompositsioonÁneurotserebrovaskulaarseteÁh„ireteÁravimiseksÁningÁmeetodÁsellesÁsisalduvaÁkurkumi?liÁvalmistamiseks
DE60231601D1 (de) Einrichtung und verfahren zur behandlung
DE60138129D1 (de) Apparat zur behandlung von zähnen
IL160933A0 (en) Methods and compositions for treating ?cap associated diseases
EP1416961A4 (fr) Composition et procede pour le traitement d'une maladie
DE60320078D1 (de) Prothesenvorrichtung und Verfahren zur Herstellung derselben
IL175044A0 (en) Single mask via method and device
GB2393202B (en) Methods of well treatment
AU2003213968A1 (en) Device for the temporary splinting of toes
DE10216633B8 (de) Halbleiteranordnung und Verfahren zur Herstellung der Halbleiteranordnung
DE50213682D1 (de) Verfahren zur herstellung von hydrogen-bis(chelato)boraten und alkalimetall-bis(chelato)boraten
GB2397040B (en) Substrate treatment device and method and encoder scale treated by this method
DE50214806D1 (de) Verfahren und vorrichtung zur abgasnachbehandlung
HK1069829A1 (en) Surface treatment composition and method
EP1389105A4 (fr) Methode de traitement
AU2002313946A1 (en) Method for curing immunopathosis and medicinal agent for carrying out said method
GB0124124D0 (en) Methods of treatment
DE60221068D1 (de) Gerät zur tiefenwirksamen Hauttherapie
GB0112216D0 (en) Method of treatment
GB0102389D0 (en) Device and method for taking moulds of feet
DE602004026067D1 (de) Gerät zur Behandlung von Füßen
GB2399500B (en) Composition and method for treatment of wounds
GB0118892D0 (en) Method of treatment
AUPR520701A0 (en) Herbal composition for the treatment of drug addiction
GB0222338D0 (en) Surface treatment of concrete

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20141214